Develops genetic medicines designed to reach targets inside cells, including treatments for Duchenne muscular dystrophy and inherited retinal diseases.
10-K for FY2025, filed Feb 26, 2026
Substantially all revenue to date has come from Vertex under a collaboration agreement; payments relate to research activities, with potential milestone payments and royalties on future product sales.
10-K for FY2025, filed Feb 26, 2026 10-K for FY2022, filed Mar 6, 2023Substantially all of our revenue to date has been derived from the Vertex Agreement. We do not expect to generate any revenue from the sale…View ↗
$25.4M
10-K for FY2025, filed Feb 26, 2026
$25.4M ↗
Vertex is a collaboration partner for the DM1 program; Entrada conducts research activities under the agreement, while Vertex is responsible for global development, manufacturing and commercialization.
10-K for FY2025, filed Feb 26, 2026 10-K for FY2022, filed Mar 6, 2023Substantially all of our revenue to date has been derived from the Vertex Agreement. We do not expect to generate any revenue from the sale…View ↗
The Vertex Agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for…View ↗
No. It lost $143.8M in FY2025.
Expanded disease focus
The older report described discovery efforts in immunology and metabolic disease alongside neuromuscular and ocular programs. The latest report describes a pipeline spanning neuromuscular and inherited retinal diseases, with an ocular candidate named.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Feb 26, 2026In immunology, we are currently leveraging multiple oligonucleotide strategies to downregulate the expression of Interferon Regulatory…View ↗
We believe our EEV Platform has broad applicability across multiple neuromuscular diseases. In addition to DMD and DM1, we are leveraging…View ↗
High unmet need continues to exist across a wide range of ocular diseases including macular dystrophies, photoreceptor diseases, optic…View ↗
We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that…View ↗
The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases. Both…View ↗
ENTR-801: The Company’s first ocular candidate is an optimized, proprietary oligonucleotide-based therapy for the potential treatment of a…View ↗
Competes with PTC Therapeutics, Catalyst Pharmaceuticals, ITF Therapeutics, Sarepta Therapeutics, Nippon Shinyaku, Avidity Biosciences, Novartis, Wave Life Sciences, Dyne Therapeutics, BioMarin Pharmaceutical, Solid Biosciences, REGENXBIO, AMO Pharma, PepGen, Design Therapeutics, Expansion Therapeutics, Sepul Bio, Nacuity Pharmaceuticals, and Reforgene
10-K for FY2025, filed Feb 26, 2026Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is…View ↗
Loading...